29.86
Collegium Pharmaceutical Inc stock is traded at $29.86, with a volume of 237.64K.
It is down -2.74% in the last 24 hours and up +0.98% over the past month.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
See More
Previous Close:
$30.70
Open:
$30.32
24h Volume:
237.64K
Relative Volume:
0.83
Market Cap:
$959.46M
Revenue:
$566.77M
Net Income/Loss:
$48.16M
P/E Ratio:
25.09
EPS:
1.19
Net Cash Flow:
$274.29M
1W Performance:
-7.01%
1M Performance:
+0.98%
6M Performance:
-7.04%
1Y Performance:
-22.58%
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Name
Collegium Pharmaceutical Inc
Sector
Phone
781-713-3699
Address
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
COLL
Collegium Pharmaceutical Inc
|
29.86 | 986.77M | 566.77M | 48.16M | 274.29M | 1.19 |
![]()
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-10-25 | Upgrade | Needham | Hold → Buy |
Jul-30-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
Jun-07-24 | Upgrade | Jefferies | Hold → Buy |
May-10-24 | Downgrade | Needham | Buy → Hold |
May-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-04-24 | Downgrade | Jefferies | Buy → Hold |
Aug-25-23 | Reiterated | Needham | Buy |
May-02-23 | Resumed | Jefferies | Buy |
Aug-08-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
Feb-15-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Aug-06-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
Jul-14-20 | Initiated | BWS Financial | Sell |
May-27-20 | Initiated | Guggenheim | Neutral |
Feb-19-20 | Resumed | Jefferies | Buy |
Oct-30-19 | Reiterated | Needham | Buy |
May-03-19 | Resumed | H.C. Wainwright | Buy |
Apr-12-19 | Resumed | Janney | Buy |
Mar-20-19 | Initiated | SunTrust | Hold |
Jan-16-19 | Reiterated | Needham | Buy |
Mar-08-18 | Reiterated | H.C. Wainwright | Buy |
Feb-07-18 | Reiterated | Needham | Buy |
Dec-05-17 | Reiterated | Needham | Buy |
Sep-11-17 | Initiated | H.C. Wainwright | Buy |
May-11-17 | Reiterated | Needham | Buy |
Sep-13-16 | Initiated | Gabelli & Co | Buy |
Jun-01-15 | Initiated | Jefferies | Buy |
Jun-01-15 | Initiated | Needham | Buy |
Jun-01-15 | Initiated | Piper Jaffray | Overweight |
View All
Collegium Pharmaceutical Inc Stock (COLL) Latest News
Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards? - Yahoo Finance
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) P/E Still Appears To Be Reasonable - simplywall.st
Institutional Tools Highlight Unusual Flow in Collegium Pharmaceutical Inc.Trade Ready Stock Watch for Short Term Published - metal.it
Real time social sentiment graph for Collegium Pharmaceutical Inc.Stock Market Watch with Smart Filters - Newser
Published on: 2025-07-29 16:28:51 - Newser
Collegium Pharmaceutical - WBFF
Identifying reversal signals in Collegium Pharmaceutical Inc.Predictive AI Engine for Smart Investing - Newser
Is Collegium Pharmaceutical Inc. stock overvalued or undervaluedStock Strategy Tracker With High Returns - jammulinksnews.com
What are the latest earnings results for Collegium Pharmaceutical Inc.Expert Picks Signals To Watch Now - jammulinksnews.com
Multi asset correlation models including Collegium Pharmaceutical Inc.Stock Entry Points Based on Technicals - Newser
Can Collegium Pharmaceutical Inc. recover in the next quarterPredictive Model for Intraday Swing Forecast - Newser
What data driven models say about Collegium Pharmaceutical Inc.’s futureAlpha Trade Flow With Risk Calibration - Newser
3 Reasons to Avoid COLL and 1 Stock to Buy Instead - Yahoo Finance
How many analysts rate Collegium Pharmaceutical Inc. as a “Buy”Turbocharged investment results - jammulinksnews.com
Why is Collegium Pharmaceutical Inc. stock attracting strong analyst attentionGet timely market insights for better trades - jammulinksnews.com
Should I hold or sell Collegium Pharmaceutical Inc. stock in 2025Invest confidently with data-driven strategies - jammulinksnews.com
What makes Collegium Pharmaceutical Inc. stock price move sharplyTremendous financial leverage - jammulinksnews.com
Published on: 2025-07-28 05:52:28 - jammulinksnews.com
Does Collegium Pharmaceutical Inc. stock perform well during market downturnsAchieve remarkable returns with smart investing - jammulinksnews.com
How Resilient Is Collegium Pharmaceutical Inc. Stock During Economic DownturnsFree Professional Portfolio Management - Newser
What risks could impact Collegium Pharmaceutical Inc. stock performanceFree Insider Trading Tips - Newser
How Collegium Pharmaceutical Inc. stock performs during market volatilityFree Stock Selection - Newser
How high can Collegium Pharmaceutical Inc. stock price go in 2025Breakneck growth rates - jammulinksnews.com
Is Collegium Pharmaceutical Inc. a good long term investmentOutstanding capital appreciation - PrintWeekIndia
Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High? - Yahoo Finance
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? - Yahoo Finance
What drives Collegium Pharmaceutical Inc. stock priceMarket-leading profit generation - PrintWeekIndia
Will Collegium Pharmaceutical Inc. stock benefit from AI tech trendsOutstanding growth strategies - jammulinksnews.com
Will Collegium Pharmaceutical Inc. stock split in the near futureFree Predictions - jammulinksnews.com
Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewswire
Collegium Pharmaceutical, Inc. Announces Q2 2025 Financial Results Release and Conference Call Details - Nasdaq
Press Release: Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 - 富途牛牛
Victory Capital Management Inc. Sells 60,823 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Bank of New York Mellon Corp Sells 10,426 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Bank of New York Mellon Corp - Defense World
Collegium Pharmaceutical Inc. Stock Analysis and ForecastSkyrocketing investment returns - jammulinksnews.com
What analysts say about Collegium Pharmaceutical Inc. stockLightning-fast capital gains - jammulinksnews.com
Collegium Pharmaceutical Inc Stock (COLL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):